Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zykadia (ceritinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BeOne Medicines, Novartis

Drug class:

ALK inhibitor

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK translocation	Soft Tissue Sarcoma	ALK translocation	Soft Tissue Sarcoma	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	ceritinib Sensitive: C1 - Off-label ceritinib Sensitive : C1	ceritinib Sensitive: C1 - Off-label ceritinib Sensitive : C1
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2
ALK C1156Y	Non Small Cell Lung Cancer	ALK C1156Y	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3